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SSurgical treatment is decisive for outcome in chondrosarcoma of the
chest wall: Apopulation-based Scandinavian SarcomaGroup study of
106 patients
Bjo¨rn Widhe, MD, and Prof. Henrik C. F. Bauer, MD, PhD
Objectives: Chondrosarcoma of the chest wall is the most frequent primary malignant chest wall tumor. Surgery
remains the only effective treatment. Sarcoma treatment in Sweden is centralized to sarcoma centers; however,
sarcomas of the chest wall have also been handled by thoracic and general surgeons.
Methods: One hundred six consecutive reports of chondrosarcomas of the rib and sternum over a 22-year period
(1980 to 2002) were studied, with a median of 9 (4 to 23) years of follow-up for survivors. Clinical files were
gathered and pathologic specimens reviewed and graded 1 to 4 by the Scandinavian sarcoma pathology group.
Surgical margins were defined as wide, marginal, or intralesional.
Results: Ninety-seven patients were treated with a curative intent. Patients operated with wide surgical margins
had a 10-year survival of 92% compared with 47% for those with intralesional resections. The 10-year survival
was 75% for patients treated at sarcoma centers and 59% for those treated by thoracic or general surgeons. Local
recurrence rate was highly dependent of the surgical margins—4% after wide resections and 73% after intrale-
sional resections. The proportion of intralesional resections was higher outside sarcoma centers. Prognostic fac-
tors (multivariate analysis) for local recurrence included surgical margin and histological grade; for metastases,
prognostic factors included histologic grade, tumor size, and local recurrence. Metastases occurred in 21 of the
patients and only 2 were cured.
Conclusions: Patients operated with wide surgical margins resulted in fewer local recurrences and better overall
survival. Patients with chest wall tumors should be referred to sarcoma centers and not to general thoracic surgery
clinics for diagnosis and treatment.
General Thoracic Surgery Widhe and BauerChondrosarcoma is the commonest primary bone malig-
nancy in adults.1 Fifteen percent of chondrosarcomas are lo-
cated in the thoracic cage, making it to the most frequent
primary malignant chest wall tumor with an annual inci-
dence of less than 0.5 per million and year.2 There are few
reports on chondrosarcoma of the thorax and none have
been population based.2,3
Compared to osteosarcoma and Ewing’s sarcoma, chon-
drosarcoma has drawn less research attention. There is no ef-
fective chemotherapy, and chondrosarcomas are relatively
radio insensitive. Hence, surgery remains the only treatment.
In Sweden, the diagnosis and treatment of patients with
primary bone tumor are referred to orthopedic sarcoma cen-
ters. This is strictly adhered to for sarcomas of long bones.
However, many patients with chest wall tumors are treated
by surgeons without experience of sarcomas.
We have reviewed treatment of patients with chondrosar-
coma of the chest wall based on a population-based series
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clinical risk factors for local recurrence and metastases and
specifically to evaluate the importance of centralized treat-
ment for outcome.
METHODS
All patients with chondrosarcoma of the chest wall diagnosed in Sweden
from 1980 to 2002 were identified from the National Swedish Cancer Reg-
ister and the Scandinavian Sarcoma Group (SSG) Register. One hundred
twenty-three patients with ICD-10 location code C413 (rib, sternum, and
clavicle) were identified. After exclusion of 9 patients with chondrosarcoma
of the clavicle, 3 patients with misclassified tumor location (2 scapulae and 1
spine), and 1 patient with radiation-induced chondrosarcoma, 110 patients
remained. Chondrosarcoma of the clavicle was excluded as it is not a flat
bone and thereby differs from rib and sternum. Clinical files were collected
for each patient from the diagnosing and treating hospitals. Pathologic spec-
imens were reviewed by the SSG Pathology Board (blinded to outcome) and
classified as grade 1 to 4, where grade 4 represents dedifferentiated chondro-
sarcoma.4 Tumor size was designated by the greatest dimension as mea-
sured from the surgical specimens. After exclusion of 4 cases because the
diagnosis of chondrosarcoma was not supported by the Pathology Board,
106 patients remained for analysis.
The following data were registered: sex, age at diagnosis, localization,
tumor size, histologic grade, surgical margin, radiotherapy, and chemother-
apy, treatment at a sarcoma center, recurrence, and survival.
Surgical margins were classified into wide, marginal, and intralesional
according to Enneking.5 Applied to chest wall chondrosarcoma, a wide sur-
gical margin required intact pleura internally, intact muscle fascia exter-
nally, and transverse rib resection> 2 cm from the tumor on both sides.
Marginal surgical margin was defined as macroscopic and microscopic
free from tumor, but< 2 cm distance, and intralesional was defined asrgery c March 2009
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SSG ¼ Scandinavian Sarcoma Group
when the lesion was macroscopically taken out in pieces or there was a mi-
croscopic positive margin.
There was a complete follow-up of median 9 (4-23) years for sur-
vivors.
Statistical analysis was performed with Statistica, statsoft; chi-square
test, Kaplan-Meier survival curve Mann-Whitney U test, Kruskal-Wallis
test, and Cox-Mantel test. Proportional hazard Cox ratio was used for mul-
tivariate analysis.
RESULTS
There were 59 male and 47 female patients, and the mean
age was 57 (13 to 85) years, equal in both sexes. Eighty-nine
of the tumors were located in the ribs and 17 in the sternum
(Figure 1). All except 3 patients had primary chondrosar-
coma (2 patients had multiple hereditary exostosis disease
and 1 had Ollier’s disease).
Treatment
Surgery was performed in 97 patients in a curative intend.
Of those one had preoperative and 6 postoperative radio-
therapy.
The remaining 9 patients were not treated with a curative
intent; 4 had radio- and chemotherapy, 1 was operated to
reduce tumor bulk, and 4 had no treatment. The reasons
for abstaining from curative surgery were high age, poor
general condition, and/or a tumor considered too large.
Surgeries were conducted at 3 orthopedic sarcoma centers
(55 patients) or at 16 different thoracic surgery or general
surgery departments in Sweden (42 patients). At the sarcoma
centers, 25 patients were treated by orthopedic surgeons and
the remaining 30 in collaboration between orthopedic and
thoracic surgeon. At the nonspecialty center, 29 patients
were operated by a thoracic surgeon and 13 by a general
surgeon.
The median tumor size was 8 (2 to 23) cm. There were no
differences in tumor size between patients treated at sarcoma
centers and those treated at nonspecialty centers.
At sarcoma centers, a median of 3 (1 to 6) ribs were re-
sected compared with 2 (0 to 4) ribs at nonspecialty centers
(P ¼ .002, Mann-Whitney U test). In 60 of 97 operations,
the defect was replaced by a net, mesh, or polytetrafluoro-
ethylene. There were no peri- or postoperative deaths.
Eighty-three percent of the sarcoma center patients had graft
prostheses compared with 41% of the patients treated at
nonspecialty centers.
Surgical margins were wide in 28% (27/97) of tumors,
marginal in 45% (44/97) (46/97), and intralesional in 27%
(26/97). Patients treated at a sarcoma center were more often
operated with wide surgical margin (P< .001, Table 1).The Journal of Thoracic and CSurvival
The estimated 10-year survival for the whole series of 106
chondrosarcoma patients was 0.64. Among the 10 non-
treated patients, all expect 1 died of the chondrosarcoma.
Six died within 1 year of diagnosis, but 4 patients lived for
3 to 10 years. Many of these patients had severe difficulties
with an enormous mass causing pain, weightiness, and so-
cial distress. Several tumors ulcerated, and it was difficult
for the patients to cover the mass with ordinary clothes.
The 10-year survival for the 97 treated patients was 0.67.
The surgical margin was an independent factor in predicting
outcome (Figure 2). It was 0.75 for patients treated at a sar-
coma center and 0.59 for those treated outside (P ¼ .04,
Cox-Mantel test; Figure 3). Patients who developed local re-
currence and/or metastases had poor outcome (Figure 4).
However, of the 97 treated patients who did not develop lo-
cal recurrence or metastases, none died of the tumor.
There appeared to be no improvement in survival over
time. Hence, the 10-year survival for the 44 patients operated
from 1980 to 1991 was 0.63, and for those 53 patients treated
from 1992 to 2002, it was 0.66.
Local Recurrence
Thirty-three of the 97 treated patients had local recurrence
of the chondrosarcoma. Hence, the local control rate for the
thoracic wall was 66%. Mean time to local recurrence was
3.5 years (0.1 to 14 years), but 4 occurred after 10 years. Re-
currence was more frequent in high-grade chondrosarcoma,
after intralesional surgical margin and treatment nonspecialty
centers (Tables 2 and 3). One of 27 patients operated with
a wide surgical margin had local recurrence compared with
19/26 after an intralesional margin. Treatment at a sarcoma
FIGURE 1. Distribution of 106 chondrosarcomas of the chest wall.ardiovascular Surgery c Volume 137, Number 3 611
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those treated at nonspecialty centers. Eight of the 20 patients
who had local recurrence but no metastases died of the tumor.
Among the 33 patients with local recurrence, 3 were not
treated and 7 had palliative radiotherapy only. Twenty-five
patients were operated for local recurrence, and 15 of these
had further local recurrences.
Metastases
None of the patients had metastases at diagnosis. How-
ever, metastatic disease was diagnosed during follow-up in
21 of the 106 patients. Pulmonary metastases were found
in all expect for 1; other metastatic locations were bone,
brain, lymph node, and liver.
Tumor grade, surgical margin, tumor size, and local recur-
rence were related to development of metastases (Tables 2
and 4). Notably, 16 of the patients with metastases had
also recurrence. None of the 19 patients with grade I chon-
drosarcoma developed metastases, whereas 7 of 8 grade
IV (dedifferentiated) tumors metastasized. The metastasis
rate was 0.42 in patients with local recurrence compared
with 0.08 in patients without a local recurrence (P ¼ .001).
DISCUSSION
Chondrosarcoma of the chest wall is the most frequent
malignant tumor of the thoracic cage. This report is the first
population-based study and included more than 100 patients
with chondrosarcoma of the chest wall. Our findings clearly
demonstrate the importance of a wide surgical margin in the
treatment of chest wall chondrosarcomas.
TABLE 1. Surgical margins
Wide Marginal Intralesional
Sarcoma center 25 26 4
Nonspecialty center 2 18 22
FIGURE 2. Kaplan-Meier analysis of surgical margins and survival.612 The Journal of Thoracic and Cardiovascular SuPrevious studies2,3,6-8 on chest wall chondrosarcoma have
been center-based and often included a small number of pa-
tients. Many studies have included chondrosarcoma of the
scapula and clavicle as well, but these were excluded in our
study because they are not intrinsic parts of the thoracic cage.
Our report is based on all chondrosarcoma patients in
Sweden over a 22-year period (8 to 9 million inhabitants).
As opposed to most cancer forms, the result of treatment
has not improved over time. In a study of chondrosarcoma
of all sites from Finland from 1970 to 1990, there was no
change in outcome over time.9 Neither we could find any
difference in outcome between those diagnosed early or
FIGURE 3. Kaplan-Meier analysis of where surgery was performed and
survival.
FIGURE 4. Kaplan-Meier analysis of local recurrence and metastasis and
survival.rgery c March 2009
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Slate in the study period. There is still no effective adjuvant
therapy for chondrosarcoma; surgery remains the only effec-
tive treatment today as it was in 1980.
We classified the surgical treatment into 3 categories:
wide, marginal, and intralesional. The 10-year survival after
wide resections was 0.92 compared with 0.47 after intrale-
sional resections. Most previous studies reported more
wide and less intralesional margins; however, the local re-
currence rates are similar.1,2,10 This discrepancy may be ex-
plained by our strict definition of surgical margins.
The treatment at the 3 sarcoma centers (55 patients) gave
dramatically higher survival and local recurrence rates than
those achieved nonspecialty centers (42 patients at 16 hospi-
tals). The outcome was better at sarcoma centers because the
surgical margin was better.
Resection of a large chest wall chondrosarcoma is a major
procedure in an elderly patient. This is why 9 patients were
not operated with a curative intent. These patients with large
tumors lived for a long time without treatment. However,
their life situation was difficult due to the chondrosarcoma.
The mass resulted in an abnormal thoracic structure and it
was troublesome to find ordinary clothes. The chondrosar-
coma ulcerated and brought a tremendous smell. Hence,
these patients were socially isolated in their last period of
their life. Because there were no peri- or postoperative
deaths in this series, maybe some of the nonoperated patients
would have survived and benefited from an operation.
The local recurrence rate was highly dependent of the sur-
gical margins. It was 0.04 after wide resections and 0.73
after intralesional resections. This confirms that our classifi-
cation of surgical margins was valid. High malignancy
grade, but not tumor size, was also an independent risk factor
for local recurrence. Fiorenza and colleagues11 reported that
local recurrence in chondrosarcoma in general (all locations)
is only relevant to survival if the patient has metastases at the
time of detection of local recurrence. However, we found
TABLE 2. Prognostic factors for local recurrence and metastasis,
multivariate analysis
Hazard ratio
(95% confidence) P value
Local recurrence
Surgical margin
Wide 1
Marginal 12.2 (10.2-14.2) <0.02
Intralesional 28.1 (26.1-30.1) <0.001
Histological grade
Low grade (grade 1 and 2) 1
High grade (grade 3 and 4) 2.8 (2.2-3.5) <0.01
Metastasis
Histological grade
Low grade (grade 1 and 2) 1
High grade (grade 3 and 4) 3.4 (2.3-4.5) <0.05
Local recurrence 24.1 (22.6 - 25.7) <0.001
Tumor size (per cm increment) 1.1 (1.0 - 1.2) <0.05The Journal of Thoracic andthat in chondrosarcoma of the chest wall, local recurrence
per se reduces survival even without distant metastasis. Pro-
gression of chest wall chondrosarcoma leads to respiratory
insufficiency and death; nearly half of the patients in our
series who had local recurrence but no metastases died of
locally progressive disease. The prognosis in patients with
metastases alone or combined with a local recurrence was
dismal. Only 2 of 19 survived in our study.
In our series, 20% of the patients developed metastasis.
Chondrosarcoma of the pelvis is associated with a higher me-
tastasis rate and chondrosarcoma of long bones with a lower
rate. We found 3 independent factors related to metastases;
first and most important was the histologic grade and second,
local recurrence. The metastasis rate was 0.42 in patients
with local recurrence compared with 0.08 in patients without
a local recurrence (P¼ .001). The third factor related to me-
tastases was tumor size. Difference in tumor size is probably
TABLE 3. Univariate analysis of clinical factors and local recurrence
Factor
Recurrence/number of
patients P value
Surgical margin <.001
Wide 1/27
Marginal 13/44
Intralesional 19/26
Histologic grade .03
1 2/19
2 15/39
3 11/31
4 5/8
Tumor size (cm)*
7 15/49 0.7
>7 14/41
Treatment center <.001
Sarcoma center 9/55
Nonspecialty center 24/42
*Missing 7 where the size was not measured.
TABLE 4. Univariate analysis of clinical factors and metastasis
Factor Metastasis/number of patients P value
Surgical margin 0.16
Wide 2/27
Marginal 10/44
Intralesional 7/26
Histologic grade <.001
1 0/19
2 5/39
3 7/31
4 7/8
Tumor size (cm)*
7 7/49 0.08
>7 12/41
Treatment center .05
Sarcoma center 12/55
Nonspecialty center 7/42
*Missing 7 where the size was not measured.Cardiovascular Surgery c Volume 137, Number 3 613
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Swhy pelvic chondrosarcoma has a higher rate of metastases
and extremity chondrosarcoma a lower rate (ie, pelvic chon-
drosarcomas are larger and extremity smaller than those of
the chest wall). Surgical margin was not an independent
risk factor for metastases, which is in line with current views
on local recurrence and metastases in sarcoma. However,
poor surgical margin was a risk factor for tumor-related death
caused by untreatable local recurrence.
Primary bone malignancies are generally handled by or-
thopedic surgeons specializing in orthopedic oncology.
The important point is that patients with chondrosarcoma
of the chest wall need to be treated by a multidisciplinary
team dedicated to sarcoma care—whether a thoracic tumor
surgeon or an orthopedic tumor surgeon performs the proce-
dure is irrelevant. Centralization of treatment of chondrosar-
coma of the chest wall will improve outcome.
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